AstraZeneca’s IL‑33 biologic Tozorakimab hits multiple Phase III successes – Meet them this September

Altesa BioSciences advances Vapendavir for rhinovirus‑triggered COPD exacerbations

GSK expands its COPD pipeline with a novel siRNA therapy (EMP‑012)

Emerging COPD treatments highlight biologics, bronchoscopic procedures & stem‑cell approaches

ReAlta’s pegtarazimod showing early promise for acute COPD exacerbations in phase 2

GSK’s Nucala gains UK backing, expanding COPD biologic access with NICE recommendation

Windward Bio and Harbour Biomed announce first Phase II dosing in SIRIUS trial for novel COPD antibody therapy

TidalSense secured $19 million to commercialise its AI-powered COPD diagnostic technology

Inhaled Biotherapeutics: Creating First-in-Class Therapies for COPD

1:00 pm - Tuesday 15th September 2026

Neutrophilic Inflammation as a therapeutic target in COPD
Novel biologics and biotherapeutics for COPD: Exploring first-in-class approaches
Particle engineering for distal lung delivery

C. Vivek Lal

Founder & Chief Scientific Officer

Alveolus Bio